Ernexa Therapeutics (ERNA) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to -$1.2 million.

  • Ernexa Therapeutics' Consolidated Net Income rose 9533.9% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.4 million, marking a year-over-year increase of 5913.92%. This contributed to the annual value of -$44.6 million for FY2024, which is 10564.43% down from last year.
  • Latest data reveals that Ernexa Therapeutics reported Consolidated Net Income of -$1.2 million as of Q3 2025, which was up 9533.9% from -$3.1 million recorded in Q2 2025.
  • Over the past 5 years, Ernexa Therapeutics' Consolidated Net Income peaked at -$1.2 million during Q3 2025, and registered a low of -$86.0 million during Q3 2021.
  • Over the past 5 years, Ernexa Therapeutics' median Consolidated Net Income value was -$5.8 million (recorded in 2024), while the average stood at -$12.2 million.
  • As far as peak fluctuations go, Ernexa Therapeutics' Consolidated Net Income tumbled by 570594.19% in 2021, and later soared by 9533.9% in 2025.
  • Ernexa Therapeutics' Consolidated Net Income (Quarter) stood at -$86.0 million in 2021, then surged by 94.78% to -$4.5 million in 2022, then tumbled by 37.07% to -$6.2 million in 2023, then grew by 6.08% to -$5.8 million in 2024, then soared by 78.54% to -$1.2 million in 2025.
  • Its Consolidated Net Income was -$1.2 million in Q3 2025, compared to -$3.1 million in Q2 2025 and -$8.2 million in Q1 2025.